UPDATED: A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on ...

Retrieved on: 2021-01-14 12:42:51

Tags for this article:

Click the tags to see associated articles and topics

UPDATED: A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on .... View article details on hiswai:

Excerpt

Merck, Amgen, Roche, and Pfizer all jumped in with similar molecules. And then, beginning in 2015, it all fell apart. The molecules, known as CETP ...

Article found on: endpts.com

View Original Article